Oral selective estrogen receptor degraders in ER+/HER2− breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence
Bing Guan, Sijia Zhang, Rong Zhou, Yawen Chen, Lulu Li, Ping He · 2026
Read Oral selective estrogen receptor degraders in ER+/HER2− breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence by Bing Guan, Sijia Zhang, Rong Zhou, Yawen Chen, Lulu Li, Ping He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13581930.txt.
Description
Guan and co-authors gather the trial evidence on a new class of oral hormone drugs for estrogen-driven breast cancer, in this 2026 review. These degraders destroy the estrogen receptor instead of merely blocking it. A recent positive trial in early disease widened the questions beyond advanced cancer.
Ten randomized trials qualified, one in the adjuvant setting and nine in metastatic disease. In early cancer, the leading drug cut the risk of invasive return by about thirty percent. Across six pooled metastatic trials, the class slowed progression by roughly a fifth against standard hormone therapy. Effects varied moderately between trials. The authors map where the class now stands, setting by setting.
Catalog record
| CREATOR | Bing Guan, Sijia Zhang, Rong Zhou, Yawen Chen, Lulu Li, Ping He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |